An A1c of 7.8% is not enough to decide whether a glenohumeral corticosteroid injection is safe today. The more useful question is whether the potential short-term relief is worth a temporary, variable rise in glucose—and whether the patient has a workable plan to monitor and respond.
Consider a 54-year-old woman with type 2 diabetes taking metformin and sitagliptin. Four months of progressive shoulder pain now makes washing her hair and fastening her bra difficult. Both active and passive motion are markedly restricted, especially external rotation, supporting adhesive capsulitis over isolated rotator cuff tendinopathy. She asks whether diabetes means she should avoid an injection.
Assuming the assessment supports adhesive capsulitis and there is no infection or other reason to avoid injection, diabetes alone does not settle the decision. The family physician’s task is to connect the treatment’s likely benefit to this patient’s glucose pattern, monitoring access, and preferences.
Decide what the injection is meant to accomplish
An injection is best framed as a possible way to reduce pain and help the patient participate in movement—not as a cure for the contracted capsule or a guarantee of lasting recovery. In a small randomized trial involving patients with diabetes and adhesive capsulitis, injection was associated with earlier improvements in pain, function, and some range-of-motion measures; the groups no longer differed at the final 24-week assessment. The trial also paired treatment with home stretching.
Ask what she most wants to do again and how much the shoulder is limiting sleep and daily function. Agree on a functional goal, such as being able to reach her hair with less pain. A gentle, tolerable range-of-motion plan matters too: pain relief is more useful if it helps her move the shoulder, rather than replacing rehabilitation.
For adhesive capsulitis, the target is the glenohumeral joint. A “shoulder shot” can refer to different structures, so confirm that the planned injection matches the working diagnosis and is being performed by someone trained to do it.
Diabetes is a risk to plan around—not an automatic veto
A local injection can still have systemic effects. Glucose may rise after an intra-articular corticosteroid injection, often becoming most noticeable during the first one to three days. The size and duration of the rise vary; studies include small numbers of patients and differ in joint, medication, dose, and monitoring method. Some shoulder-specific observations found glucose remained above baseline beyond the first few days, so do not promise that it will normalize by day three.
The A1c of 7.8% is relevant background, but it is not a measurement of today’s glucose or a validated, stand-alone go/no-go cutoff for this procedure. Before recommending a plan, compare it with the patient’s individualized diabetes goal and recent home readings. Ask about prior reactions to steroid treatment, current medicines, symptoms of marked hyperglycemia, and whether she can check glucose and contact the care team if needed.
For this patient, the listed medicines are oral agents, with no insulin regimen provided. That is a reason to avoid inventing an insulin correction plan—not a reason to assume she cannot have a temporary glucose rise. Unless her diabetes clinician advises otherwise, do not tell her to stop or increase her usual medicines preemptively.
Make the safety plan before the procedure
A useful pre-injection conversation covers four points:
- What to expect: Explain that glucose can rise even though the steroid is injected into a joint, and that the change is usually temporary but unpredictable.
- How to monitor: Agree on a practical plan to check more often than usual during days one through three. If readings remain above her usual range after that, continue monitoring and contact the care team rather than assuming the effect has passed.
- Who to call—and when: Decide in advance what level or pattern of glucose elevation should prompt a call, using her usual readings and existing diabetes plan. There is no single threshold that fits every patient. Advise urgent assessment for severe symptoms such as confusion, rapid breathing, or inability to keep fluids down.
- What not to change alone: Keep her usual diabetes medicines unless her clinician gives different instructions. Do not make a new dose adjustment based on a brief rise without an agreed plan.
If she does not have a meter or cannot check reliably, that should prompt coordination—not a vague instruction to “watch the sugar.” Arrange a workable monitoring and contact plan with the primary care or diabetes team. If a safe plan cannot be put in place for an elective injection, discuss postponing it and using other symptom-management options in the meantime.
Avoid the shortcuts that undermine shared decisions
“Diabetes makes steroid injections unsafe.” That turns a manageable risk into a blanket prohibition and may leave a patient with significant pain without discussing potential benefit or alternatives.
“It’s only a local injection, so glucose will not change.” Local delivery does not eliminate systemic absorption or transient hyperglycemia.
“The A1c tells me exactly what will happen.” It does not reveal the patient’s usual daily readings, individual target, or personal response to a prior injection.
“The glucose rise will be over in 72 hours.” The first few days deserve particular attention, but duration varies. Give a follow-up plan for readings that remain elevated.
“Increase medication just in case.” A short-lived glucose excursion does not automatically justify changing a chronic regimen. Keep any medication adjustment individualized and coordinated.
Practical takeaways
- Type 2 diabetes alone does not automatically rule out a glenohumeral steroid injection for adhesive capsulitis.
- Discuss likely short-term benefit alongside the possibility of a temporary, variable glucose rise.
- Use the patient’s recent glucose pattern, individualized goal, medicines, prior steroid response, and ability to monitor—not A1c alone—to shape the plan.
- Agree on more frequent monitoring during days one through three, and continue if readings remain above the patient’s usual range.
- Do not advise unsupervised medication changes; make the monitoring and contact plan part of the treatment decision.
